Onkologie. 2011:5(2):102-104
Role of cetuximab in long-term survival of patient with metastatic colorectal carcinoma
- Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Patients with metastatic colorectal cancer (mCRC) should receive all five drugs active in this disease during the overall course of their
treatment: These drugs consist of three chemotherapeutic agents: 5-fluorouracil/leucovorin (5-FU/LV), irinotecan and oxaliplatin and
two monoclonal antibody: bevacizumab directed against the vascular endothelial growth factor and the epidermal growth factor
receptor inhibitor cetuximab or panitumumab. Treatment options for third-line therapy depend on what agents have been used in
previous therapy. In patients with prior treatment with 5-FU, oxaliplatin, and irinotecan, treatment with the combination of cetuximab
and irinotecan is an attractive option.
Keywords: colorectal cancer, chemotherapy, radiotherapy, targeted therapy – cetuximab
Published: April 1, 2011 Show citation
References
- Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810.
Go to original source... 
Go to PubMed... - Cunningham D, Humblet Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor positive, irinotecan-refractory metastatic colorectal cancer [abstract no. 1012]. Proc Am Soc Clin Oncol 2003; 22: 252 plus oral presentation.
- Saltz L, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225 (Erbitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [abstract no. 504]. Proc Am Soc Clin Oncol 2002; 21(1): 127.
- Tabernero JM, Van Cutsen E, Saestre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5fluorouracil (FU)/folinic acid (FA) (FOLFOX4) in the first-line treatment of patiens with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. Proc Am Soc Clin Oncol 2004; 23(Abstr. 3512). Go to original source...
- Van Cutsen E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and FUFA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Journal of Clinical Oncology 2007(Suppl 18) Abstract 4000. Go to original source...
- Kocakova I, Kocak I, Spelda S, Vyzula R. Cetuximab and irinotecan in chemoresistant metastatic colorectal cancer: retrospective analysis. Annals of Oncology 2007; 18(Suppl 7): P-0188. World Congress on Gastrointestinal Cancer Barcelona, Spain. Go to PubMed...